OptiBiotix chief hails commercial progress

OptiBiotix chief hails commercial progress

A York business, which develops compounds to tackle obesity, high cholesterol and diabetes, has reported widening first-half losses but its chief executive has hailed a period of “significant progress” that included deals with two multinationals.

However, chief executive Stephen O’Hara praised the progress the business has made as it continues to commercialise its products.

“OptiBiotix has made significant progress in the last six months advancing our development programmes, building our IP portfolio, and signing commercial agreements with two multinationals,” he said.

See the article in full at InsiderMedia.com

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.